<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00131469</url>
  </required_header>
  <id_info>
    <org_study_id>IBMD-OI</org_study_id>
    <secondary_id>UL1RR024140</secondary_id>
    <nct_id>NCT00131469</nct_id>
  </id_info>
  <brief_title>Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta</brief_title>
  <acronym>OI</acronym>
  <official_title>A Study to Assess the Effectiveness of Teriparatide (FORTEO) for Increasing Bone Mass and Improving Bone Strength in Adults Affected With Osteogenesis Imperfecta (OI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osteogenesis Imperfecta Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which
      is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in
      adults affected with Osteogenesis Imperfecta (OI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which
      is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in
      adults affected with Osteogenesis Imperfecta (OI). Osteogenesis imperfecta is an inherited
      disorder of type I collagen, a major component of bones, and is characterized by multiple
      fractures and deformities. OI affects approximately 1-2 of every 10,000 individuals.
      Virtually all of the studies of potential treatments for OI have evaluated the effects of
      medications only on children with OI. There is no cure for osteogenesis imperfecta and there
      is no established medical therapy for adults with the disorder. There are very limited data
      concerning the usefulness of parathyroid hormone therapy in OI. An effective anabolic therapy
      for the treatment of adult patients with OI could be a valuable asset to the affected
      patients. In this study, the working hypothesis is that individuals affected with OI who are
      treated with Forteo will experience increased spine and hip bone mineral density and an
      increase in bone strength. Although Forteo is not expected to change the defect in the
      collagen produced, but is postulated to increase the quantity of bone formed and improve bone
      strength.

      This will be a placebo controlled, double blinded trial; half the patients will receive
      Forteo 20 ug/day SQ. Adult patients (age at least 18 yrs) with OI will be enrolled for a
      treatment duration of 18 months. Blood, urine, and bone density/strength tests will be done
      during the study to assess efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spine Bone Mineral Density (BMD)</measure>
    <time_frame>baseline and 18 months</time_frame>
    <description>bone density by dual energy xray absorptiometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Hip BMD</measure>
    <time_frame>baseline and 18 months</time_frame>
    <description>bone density by dual energy xray absorptiometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Teriparatide (FORTEO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily SQ placebo for 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide (FORTEO)</intervention_name>
    <description>Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily</description>
    <arm_group_label>Teriparatide (FORTEO)</arm_group_label>
    <other_name>FORTEO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous established diagnosis of Osteogenesis Imperfecta AND

          -  &gt; 2 previous adult fractures, AND/OR

          -  BMD at lumbar spine, femoral neck or total hip T score &lt; -2.0

        Exclusion Criteria:

          -  Open epiphyses.

          -  History of external beam radiation to the skeleton.

          -  Pagets disease.

          -  Bone metastases or skeletal malignancies.

          -  Total lifetime exposure to any antiresorptive medication &lt; 90 days (Primary
             Inclusion).

          -  Treatment with any antiresorptive medication 12 months proceeding enrollment -
             (Secondary Inclusion).

          -  Women with OI who are pregnant or unwilling to use 1 form of contraception.

          -  Vitamin D insufficiency (25-hydroxyvitamin D &lt;15ng/ml)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric S Orwoll, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Shapiro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan Lee, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Balor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra Veith, CRA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, Department of Molecular and Human Gentics</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://oif.org</url>
    <description>Osteogenesis Imperfecta Foundation</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 16, 2005</study_first_submitted>
  <study_first_submitted_qc>August 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2005</study_first_posted>
  <results_first_submitted>March 14, 2019</results_first_submitted>
  <results_first_submitted_qc>April 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2019</results_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Eric Orwoll, MD</investigator_full_name>
    <investigator_title>Professor Of Medicine</investigator_title>
  </responsible_party>
  <keyword>Osteogenesis Imperfecta</keyword>
  <keyword>Brittle Bone Disease</keyword>
  <keyword>Fragility Fractures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant was formally enrolled but then dropped out before the first study treatment was administered.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Teriparatide (FORTEO)</title>
          <description>Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
Teriparatide (FORTEO): Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Daily SQ placebo for 18 months
Placebos</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>scan not analyzable</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Teriparatide (FORTEO)</title>
          <description>Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
Teriparatide (FORTEO): Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Daily SQ placebo for 18 months
Placebos</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="12.9"/>
                    <measurement group_id="B2" value="41.2" spread="10.1"/>
                    <measurement group_id="B3" value="41" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="38"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Spine Bone Mineral Density (BMD)</title>
        <description>bone density by dual energy xray absorptiometry</description>
        <time_frame>baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide (FORTEO)</title>
            <description>Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
Teriparatide (FORTEO): Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily SQ placebo for 18 months
Placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Spine Bone Mineral Density (BMD)</title>
          <description>bone density by dual energy xray absorptiometry</description>
          <units>percentage of change in g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="1.5"/>
                    <measurement group_id="O2" value="2.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Hip BMD</title>
        <description>bone density by dual energy xray absorptiometry</description>
        <time_frame>baseline and 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide (FORTEO)</title>
            <description>Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
Teriparatide (FORTEO): Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Daily SQ placebo for 18 months
Placebos</description>
          </group>
        </group_list>
        <measure>
          <title>Total Hip BMD</title>
          <description>bone density by dual energy xray absorptiometry</description>
          <units>percentage of change in g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2"/>
                    <measurement group_id="O2" value="-2.4" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Teriparatide (FORTEO)</title>
          <description>Once daily SQ administration of Teriparatide (FORTEO) 20 ug for 18 months
Teriparatide (FORTEO): Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Daily SQ placebo for 18 months
Placebos</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eric Orwoll</name_or_title>
      <organization>OHSU</organization>
      <phone>15034940225</phone>
      <email>orwoll@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

